Cosmetic surgery tourism... Time for regulation?

Cosmetic surgery tourism... Time for regulation?

Comments

Post a Comment

Popular posts from this blog

GLP-1 Hub 2026: Approved Drugs, Pills vs Injections, Retatrutide & Safety

Image
Home › GLP-1 Hub By Dr. Frank Yap, MD  |  Last updated: October 2026  |  Purpose: evidence and safety education, not individual medical advice Quick Answer GLP-1 therapy now includes injections and, since 2025–2026, two FDA-approved pills : oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron) , approved April 1, 2026 as the first non-peptide oral GLP-1 for weight management. Retatrutide is not approved anywhere ; it remains in Phase 3 testing. Compounded and gray-market GLP-1 or peptide products are not FDA-approved, and the FDA issued warning letters to telehealth compounders in March 2026. Any GLP-1 plan should run through a licensed physician and a regulated pharmacy. On this page Approval status at a glance Pills vs injections Retatrutide: what is and isn't known Safety, side effects and compounding risks Evidence grades (CEBM) Explore the full GLP-1 & peptide library Using this hub with AI assistants FA...
Read more

Semaglutide vs Tirzepatide Muscle Loss: Which Preserves More Lean Mass?

Image
Updated October 2, 2026 Semaglutide and tirzepatide can produce substantial weight loss, but an important question has emerged alongside the popularity of GLP-1-based obesity medicines: How much of the weight lost is fat, and how much is lean mass? The question is more complicated than it first appears. Studies of semaglutide and tirzepatide show that both drugs reduce fat mass and also reduce lean mass during weight loss. However, lean mass is not synonymous with skeletal muscle , and results from separate trials cannot be interpreted as a direct head-to-head comparison of muscle preservation. A 2026 systematic review and meta-analysis of 20 randomized controlled trials involving 15,782 participants estimated that lean mass accounted for approximately 35.2% of weight lost with semaglutide and 25.4% with tirzepatide . However, the authors did not establish that tirzepatide preserves functional skeletal muscle better than semaglutide. The analysis also found that ad...
Read more

How to Prevent Muscle Loss on GLP-1 Drugs: Protein, Resistance Training & Body Composition Guide (2026)

Image
Updated September 2026 GLP-1-based medicines have changed the treatment of obesity by making substantial, sustained weight loss possible for many people. But as the scale goes down, an important question follows: How much of the weight being lost is fat, and how much is lean tissue? This matters because long-term health is not determined by body weight alone. Preserving skeletal muscle, strength, physical function and nutritional adequacy is particularly important during substantial weight loss. The good news is that current evidence does not support the idea that GLP-1 therapies simply “eat away” muscle. Most weight lost with semaglutide and tirzepatide is fat mass. At the same time, measurable reductions in lean mass can occur, particularly during large or rapid weight loss. The most defensible strategy is therefore not to avoid effective obesity treatment, but to improve the quality of weight loss with adequate protein, progressive re...
Read more

Semaglutide vs Tirzepatide vs Orforglipron: Which GLP-1 Drug Is Best for Weight Loss and Diabetes in 2026?

Image
GLP-1 & Obesity Medicine Guide • Updated October 2026 Semaglutide, tirzepatide and orforglipron represent three important stages in the evolution of incretin-based medicine: an established injectable GLP-1 receptor agonist, a dual GIP/GLP-1 agonist with greater average weight loss, and a next-generation oral GLP-1 receptor agonist designed to deliver GLP-1 therapy without an injection. But the phrase “best GLP-1 drug” can be misleading. These medicines do not have identical mechanisms, routes of administration, dose scales, indications or clinical-outcome evidence. And the headline weight-loss percentages come from different trials, so they cannot simply be placed in one league table as though the three drugs were tested against each other in a single randomized trial. The current evidence nevertheless gives us a useful framework. Tirzepatide currently has the strongest direct evidence for greater weight loss than semaglutide. Semaglutide remains a benchmark therapy w...
Read more

Ozempic vs Wegovy vs Mounjaro vs Trulicity: Which GLP-1 Drug Is Best for Weight Loss and Diabetes in 2026?

Image
GLP-1 & Obesity Medicine Guide • Updated October 2026 Ozempic, Wegovy, Mounjaro and Trulicity are all once-weekly injectable medicines, but they are not the same drug and they are not approved for exactly the same purposes. Ozempic and Wegovy contain semaglutide ; Trulicity contains dulaglutide ; and Mounjaro contains tirzepatide , a dual GIP/GLP-1 receptor agonist. For weight loss , the strongest head-to-head evidence currently favors tirzepatide over semaglutide. In the 72-week SURMOUNT-5 trial, adults with obesity but without diabetes lost an average of 20.2% of body weight with tirzepatide versus 13.7% with semaglutide . For type 2 diabetes , tirzepatide has also produced greater weight loss and HbA1c reduction than semaglutide 1 mg in SURPASS-2, although that trial does not prove that tirzepatide is superior to every semaglutide dose or every patient-specific regimen. At the same time, “best” depends on the goal . Semaglutide has extensive cardiovascular and kid...
Read more

Ozempic vs Wegovy vs Mounjaro vs Zepbound: Differences, Evidence, Safety and Access (2026)

Image
By Dr. Frank Yap, MD, One Day Media Network · Published 2026-10-04 · Last updated 2026-10-04 · Reading time about 12 minutes Quick Answer Ozempic and Wegovy are the same drug (semaglutide); Mounjaro and Zepbound are the same drug (tirzepatide). Ozempic and Mounjaro are labeled for type 2 diabetes, while Wegovy and Zepbound are labeled for weight management. In the head-to-head SURMOUNT-5 trial, tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide at 72 weeks. The right choice depends on diagnosis, coverage, tolerability and other conditions. In this article Are these four drugs different or the same? Side-by-side comparison table Which produces more weight loss? Heart, kidney, liver and sleep apnea indications Side effects and who should avoid the...
Read more

Tirzepatide vs Semaglutide: Zepbound vs Wegovy for Weight Loss, Diabetes & Heart Health in 2026

Image
2026 Evidence-Based Guide Last updated: October 6, 2026. Tirzepatide and semaglutide are two of the most important incretin-based medicines used for obesity and metabolic disease. The key question is no longer simply whether they work. It is which drug has the better evidence for a particular goal, patient and indication . Bottom line: In the strongest direct head-to-head obesity trial, tirzepatide produced greater average weight loss than semaglutide : 20.2% versus 13.7% at 72 weeks in SURMOUNT-5. However, semaglutide has important advantages, including a mature cardiovascular-outcomes evidence base, an oral Wegovy formulation, an FDA-approved 7.2-mg injectable dose for selected adults, pediatric obesity approval for Wegovy injection, and an FDA-approved MASH indication for Wegovy injection. This guide focuses on U.S. regulatory labeling and major published evidence. Drug approvals, formulations, availability and prescribing rules differ by co...
Read more

GLP-1 Manual 2026: The Complete Guide to GLP-1 Drugs, Benefits, Risks, Dosing, Muscle Loss & Long-Term Strategy

Image
Updated October 3, 2026 GLP-1 therapy has moved far beyond the simple phrase “weight-loss drugs.” Semaglutide, tirzepatide and newer oral and multi-receptor therapies are reshaping obesity, diabetes and cardiometabolic care. But a useful GLP-1 guide needs two columns: what these medicines can do, and what they can cost if treatment is poorly matched, escalated too quickly, or accompanied by inadequate nutrition and physical activity. This GLP-1 manual brings the major evidence together in one place: the drug family, approved 2026 therapies, emerging candidates, expected weight loss, cardiovascular and kidney outcomes, liver and sleep-apnea data, adverse effects, contraindications, oral contraceptive issues, peri-procedural considerations, muscle and bone preservation, monitoring and what happens when treatment is stopped. The central idea: GLP-1 therapy should not be judged by the scale alone. The clinically meaningful goal is better health w...
Read more

Telehealth Peptide Providers 2026: How to Compare Prescription GLP-1s, Other Peptides, Compounding, Clinical Oversight and Pharmacy Sources

Image
A practical 2026 guide to comparing online peptide and GLP-1 care, with a focus on prescription legitimacy, FDA approval, compounding, clinician oversight, pharmacy sourcing, cost and patient safety. Last updated: October 2, 2026 Scope of this guide: This article primarily examines the U.S. telehealth market because FDA approval and U.S. compounding rules are central to the current peptide landscape. Availability, prescribing rules and product registration differ substantially in other countries. Telehealth has changed how patients access peptide-based medicines. Instead of starting with a traditional clinic visit, patients can often complete an online health assessment, meet a clinician by video or messaging, receive a prescription when medically appropriate, and have medication delivered through a pharmacy. The problem is that the word “peptide” now covers very different categories of products. An FDA-approved prescripti...
Read more

Fatty Liver (MASLD/MASH): Diagnosis, FIB-4 Score, Treatment Ladder & Supplement Evidence 2026

Image
OneDayMD Research Team • Updated October 2026 A practical guide to metabolic dysfunction-associated steatotic liver disease: how to recognize fatty liver, estimate fibrosis risk with FIB-4, decide when FibroScan or specialist assessment is needed, and understand what actually works in 2026. The key idea: fatty liver is not simply a problem of “too much fat in the liver.” The clinically important question is whether there is inflammation and, especially, significant liver fibrosis . That changes the level of risk and the treatment conversation. OneDayMD bottom line: For most adults with suspected MASLD, the practical pathway is identify metabolic risk → calculate FIB-4 → use a second non-invasive test when indicated → stage fibrosis → treat weight, glucose, lipids and cardiovascular risk → consider MASH-targeted medication when significant fibrosis is present . Supplements remain secondary because guideline-level evidence is not strong enough to recom...
Read more